Reported Earlier, Actinium To Present Improved Survival Outcomes In TP53 Positive Patients At The EHA 2024 and Long-Term Efficacy Results In Older Patients Receiving An Iomab-B Led Bone Marrow Transplant In The Phase 3 SIERRA Trial
Reported Earlier, Actinium To Present Improved Survival Outcomes In TP53 Positive Patients At The EHA 2024 and Long-Term Efficacy Results In Older Patients Receiving An Iomab-B Led Bone Marrow Transplant In The Phase 3 SIERRA Trial
早些時候報道，Actinium將在2024年EHA上顯示TP53陽性患者的存活率有所改善，在SIERRA的3期試驗中，接受Iomab-B主導的骨髓移植的老年患者將獲得長期療效
- Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did not receive Iomab-B (hazard ratio=0.23, p=0.0002) in the Phase 3 SIERRA Trial
-在接受Iomab-B主導的異基因骨髓移植的TP53突變患者中，觀察到的總存活期中位數爲5.49個月，而在SIERRA3期試驗中未接受Iomab-B（危險比=0.23，p=0.0002）的患者的總存活期中位數爲1.66個月
- Long-term efficacy results in older patients with active relapsed or refractory acute myeloid leukemia also observed in the SIERRA trial
-在SIERRA試驗中也觀察到活動性復發或難治性急性髓系白血病的老年患者的長期療效
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。